Michaela Barbier
YOU?
Author Swipe
View article: Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co‐Design Approach With General Practitioners and Patients
Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co‐Design Approach With General Practitioners and Patients Open
Proton Pump Inhibitors (PPIs) are widely prescribed medications globally. PPIs are often inappropriately used – for example, prescribed without a clear indication, at higher‐than‐necessary doses, or for longer durations than needed – resul…
View article: Contributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data
Contributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data Open
Background The concept of Value-Based Health Care (VBHC) seeks to maximise patient value by optimising health outcomes considering costs. However, necessary data are not readily available. In Switzerland, hospital accounting is disconnecte…
View article: A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland Open
BACKGROUND AND OBJECTIVE: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus …
View article: DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care
DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care Open
Objectives Proton pump inhibitors (PPIs) are widely prescribed medications and commonly used for the treatment of gastric acid-related disorders. Nevertheless, PPIs are often overused leading to potential adverse effects and unnecessary he…
View article: Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer Open
Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to an…
View article: Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study – outcomes, adherence, and costs
Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study – outcomes, adherence, and costs Open
Background The success of colorectal cancer (CRC) screening depends mainly on screening quality, patient adherence to surveillance, and costs. Consequently, it is essential to assess the performance over time. Methods In 2000, a closed coh…
View article: A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland Open
Introduction Pembrolizumab monotherapy or in combination with chemotherapy are two new treatment options for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) and high (≥ 50%) programmed death ligand 1 (PD-L1) expres…